MBS301 drug study for HER2-positive advanced cancers
Part of Cancer clinical trials.
This Phase 1 study tests MBS301, a new treatment, for people with HER2-positive advanced solid tumors. It mainly looks at safety and how the drug works, especially for cancers that have returned or spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a HER2-positive solid tumor confirmed by biopsy or cell sample
- Your cancer is back or has spread, and prior standard treatment either didn’t work, wasn’t tolerated, or doesn’t exist
- A doctor can measure your tumor on scans (or it meets the study’s “not measurable” rules)
- Your overall activity level is fairly good (ECOG 0–1)
- Your expected survival is more than 12 weeks
- Your body-blood and organ tests meet safety thresholds (blood counts, liver, kidneys, and clotting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
This early-phase study tests KM501, a treatment targeting HER2, in adults with solid cancers that have worsened and for which standard treatment isn’t available or not tolerated. The goal is to see whether KM501 is safe and whether it can shrink or control the cancer in this group.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new HER2-positive Recurrent or Metastatic Malignant Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.